


SUNWAY EDUCATION GROUP

COVID-19 Advisory 40: VACCINATION UPDATES & ROUND 2 ASTRAZENECA BOOKINGS OPEN TODAY

Dear Students and Staff Members of the Sunway Education Group (SEG) community,

1. To date, a total of 10.5 million individuals, Malaysians and non-Malaysians alike, have registered for the COVID-19 vaccination under the National COVID-19 Immunisation Programme (NCIP). **I must thank and congratulate each and every one of you who have registered including those of you who have received your vaccination.** I know that some may have concerns about the remote risks involved but do know that getting vaccinated means we are taking one step closer towards herd immunity and **protecting not just ourselves, but our loved ones and those around us.**
2. As of 21 May, over 2.29 million vaccination doses have been administered nationwide. This includes over 83,000 vaccination doses on Friday, 19 May – the highest single-day record since the NCIP began. **The Special Committee on Ensuring Access to COVID-19 Vaccine Supply (JKJAV)** estimates that this will increase as more vaccine supplies are received. The ramping up of vaccination rates is a much-welcomed development.



3. In April, the government allowed for all residents of KL and Selangor to opt-in for the **AstraZeneca vaccine** and we informed our Sunway community to register in Advisory 37. Among the 268,000 individuals who booked, including my own family and that of Prof Abhi Veerakumarasivam, Dean of School of Medicine and Life Sciences, is **Mr Danial Rahman**, the Director of the SEG CEO's Office who **recently shared his experience getting the AstraZeneca vaccination together with his wife in The Star newspaper.** Please spare some time to read the column which contains useful tips when going for your vaccination appointment: **"Get Vaccinated, save lives"**
<https://www.thestar.com.my/opinion/columnists/whats-your-status/2021/05/21/get-vaccinated-save-lives>

What's Your Status?
Get vaccinated, save lives

MY wife and I received our AstraZeneca vaccination last week at the World Trade Centre Kuala Lumpur (WTCKL)

Danial Rahman





Thumbs-Up: Prof Abhi's family after getting their AstraZeneca vaccination

4. **Round 2 of AstraZeneca vaccination bookings opens today:** The government has announced that those interested to opt-in for the AstraZeneca vaccination can do so online **beginning 12pm today, 23 May 2021, at www.vaksinovid.gov.my**. It will first be opened to those aged 60 years and above residing in Klang Valley, Penang, Johor, Kuching and Miri. It is expected that the bookings will be open to those below 60 after 26 May. JKJAV announced that 1.24 million AstraZeneca vaccine doses will be made available. So, as per our previous advisory, **we encourage our students and staff to take this opportunity to get vaccinated as soon as possible**. Please of course familiarise yourself with all relevant information about the AstraZeneca vaccine beforehand – we have included some information published by JKJAV together with this advisory. It is also worth reading that **new real-world evidence indicates** that the AstraZeneca vaccines, in tens of millions of vaccinated people globally, are demonstrating effectiveness against COVID-19 death, hospitalisation and transmission.



5. As we are all now undergoing MCO 3.0, and as daily COVID-19 infection (and death) rates continue to climb, we are reminded of how challenging managing this pandemic really is. The vaccinations truly are our source of hope. Therefore, let us play our part by getting registered and vaccinated as soon as possible.

#LindungDiriLindungSemua
#ProtectSelfProtectAll

Professor Elizabeth Lee
 Chief Executive Officer
 Sunway Education Group
23 May 2021

OPENING SOON ASTRAZENECA VACCINE BOOKING for SENIOR CITIZENS

23 MAY 2021 (SUNDAY)

at **www.vaksinovid.gov.my** *

Reservations are on a *first-come, first-served* basis

BOOKING REQUIREMENTS

- Aged 60 years and above
- Have previously registered for vaccination under the National COVID-19 Immunisation Programme
- Live in Johor, Penang, Kuala Lumpur, Sarawak or Selangor
- Please ensure your NRIC number and address listed on MySejahtera are correct

* *Please familiarise yourself with all relevant information about the vaccine before booking.*



**LINDUNG DIRI,
LINDUNG SEMUA.**



SPECIAL COMMITTEE ON ENSURING ACCESS
TO COVID-19 VACCINE SUPPLY (JKJAV)

Notice: Beware of fake news circulation



<https://www.vaksinovid.gov.my/en/register> is the link for registration of the National COVID-19 Immunisation Programme (PICK) and not for the AstraZeneca vaccine

vaksinovid.gov.my

**LINDUNG DIRI,
LINDUNG SEMUA.**



SPECIAL COMMITTEE ON ENSURING ACCESS
TO COVID-19 VACCINE SUPPLY (JKJAV)

An analysis on potential benefits and risks for AstraZeneca COVID-19 vaccine based on age groups for the Malaysian population

1

AstraZeneca COVID-19 vaccine is safe and has a good outcome for the vast majority of the target group.

However, rare cases of unusual blood clots with low platelets have been reported in approximately **1 in 100,000 people** who have received the vaccine.

An analysis of age-specific potential benefits and risks of the AstraZeneca COVID-19 vaccine for Malaysians is illustrated as follows:

Data will be updated once more information on this matter is made available.

**AstraZeneca
COVID-19 Vaccine
For Malaysians**

vaksinovid.gov.my



**LINDUNG DIRI,
LINDUNG SEMUA.**



SPECIAL COMMITTEE ON ENSURING ACCESS TO COVID-19 VACCINE SUPPLY (JKJAV)

Weighing up the potential benefits and risks of AstraZeneca COVID-19 vaccine for 100,000 people

2

POTENTIAL BENEFITS*

AGE GROUP

POTENTIAL RISKS

Estimated preventable ICU admissions

Blood clots with low platelets



*Estimated based on CPRC data from 1 January 2021 until 23 April 2021 and Clin_COVID-data 2020

Source: European Medicines Agency (EMA) Annex to Vaxzevria Art.5.3

Data will be updated once more information on this matter is made available.

**AstraZeneca
COVID-19 vaccine
Estimated preventable
ICU admissions**

vaksinovid.gov.my



**LINDUNG DIRI,
LINDUNG SEMUA.**



SPECIAL COMMITTEE ON ENSURING ACCESS TO COVID-19 VACCINE SUPPLY (JKJAV)

Analysis of the potential benefits and risks of the AstraZeneca COVID-19 vaccine in relation to admissions to the Intensive Care Unit (ICU)

3

Potential Benefits

Analysis shows that with increasing age, the higher the benefits against ICU admissions due to COVID-19 when compared to rare incidence of unusual blood clots with low platelets.

For example, ICU admissions prevented for ages 60-69 were almost **two times higher** compared to ages 40-49.

Potential Risks

The incidence of blood clots with low platelets after vaccination for ages 40-49 is **2.1 per 100,000**. The risk then halves to **1 per 100,000** for ages 60-69, and drops to about **0.5 per 100,000** for ages 70-79.

Data will be updated once more information on this matter is made available.

**AstraZeneca
COVID-19 Vaccine
Benefits & risks**

vaksinovid.gov.my




**LINDUNG DIRI,
LINDUNG SEMUA.**



SPECIAL COMMITTEE ON ENSURING ACCESS TO COVID-19 VACCINE SUPPLY (JKJAV)

Weighing up the potential benefits and risk of AstraZeneca COVID-19 vaccine for 100,000 people

4



*Estimated based on CPRC data from 1 January 2021 until 23 April 2021 and Clin_COVID-data 2020

Source: European Medicines Agency (EMA) Annex to Vaxzevria Art.5.3

Data will be updated once we receive more information on the matter.

**AstraZeneca
COVID-19 vaccine
Estimated preventable deaths**

vaksinovid.gov.my



**LINDUNG DIRI,
LINDUNG SEMUA.**



SPECIAL COMMITTEE ON ENSURING ACCESS TO COVID-19 VACCINE SUPPLY (JKJAV)

Analysis of the potential benefits and risks of the AstraZeneca COVID-19 vaccine in relation to deaths due to COVID-19

5

Potential Benefits

Analysis suggests that mortality rates due to COVID-19 were higher among elderly patients. It is far much higher compared to blood clot incidences with low platelets.

For example, preventable deaths for ages 60-69 were **three times higher** when compared to ages 40-49.

Potential Risks

The incidence of blood clots with low platelets after vaccination for ages 40-49 is **2.1 per 100,000**. The risk then halves to **1 per 100,000** for ages 60-69, and drops to about **0.5 per 100,000** for ages 70-79.

Data will be updated once more information on this matter is made available.

AstraZeneca
COVID-19 Vaccine
Benefits & risks

vaksinovid.gov.my



LINDUNG DIRI,
LINDUNG SEMUA.



SPECIAL COMMITTEE ON ENSURING ACCESS
TO COVID-19 VACCINE SUPPLY (JKJAV)

6

Summary

Based on the analysis of the Malaysian data, the benefits/risks ratio is more favourable as the age increases.

References

1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104840. Epub ahead of print. PMID: 33835769. <https://www.nejm.org/doi/full/10.1056/NEJMoa2104840>
2. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skatter TH, Tjønnfjord GE, Holme PA. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104882. Epub ahead of print. PMID: 33835768. <https://www.nejm.org/doi/full/10.1056/NEJMoa2104882>
3. COVID-19 vaccines: JCVI recommendations on the use of the AstraZeneca vaccine <https://publichealthmatters.blog.gov.uk/2021/04/30/covid-19-vaccines-jcvi-recommendations-on-the-use-of-the-AstraZeneca-vaccine/#:~:text=JCVI%20currently%20advises%20that%20it,the%20AstraZeneca%20vaccine%2C%20if%20available.>
4. Annex to Vaxzevria Art.5.3 - Visual risk contextualisation, European Medicines Agency. 23 Apr 2021. https://www.ema.europa.eu/en/documents/chmp-annex/annex-vaxzevria-art53-visual-risk-contextualisation_en.pdf

AstraZeneca
COVID-19 Vaccine

vaksinovid.gov.my



LINDUNG DIRI,
LINDUNG SEMUA.



SPECIAL COMMITTEE ON ENSURING ACCESS
TO COVID-19 VACCINE SUPPLY (JKJAV)